期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

传统及新型调脂药物在非酒精性脂肪性肝病治疗中的价值

Application of lipid-modulating drugs in treatment of non-alcoholic fatty liver disease
下载PDF
导出
摘要 非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是目前最常见的肝脏疾病,其疾病谱包括非酒精性肝脂肪变(non-alcoholic hepatic steatosis,NAS)、非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)、肝硬化和肝细胞性肝癌(hepatocellular carcinoma,HCC)[1]。
作者 张瑞祥 孙烁烁 韦晓 刘超 ZHANG Ruixiang;SUN Shuoshuo;WEI Xiao
机构地区 南京中医药大学附属中西医结合医院内分泌科、江苏省中医药研究院、国家中医药管理局瘿病证治重点研究室
出处 《内科理论与实践》 2023年第3期215-220,共6页 Journal of Internal Medicine Concepts & Practice
关键词 非酒精性脂肪肝 非酒精性脂肪性肝炎 调脂药 肝损伤
分类号 R575.5 [医药卫生—消化系统]
  • 相关文献

参考文献2

二级参考文献52

  • 1Marko Duvnjak,Ivan Leroti,Neven Bari,Vedran Tomai,Lucija Virovi Juki,Vedran Velagi.Pathogenesis and management issues for non-alcoholic fatty liver disease[J].World Journal of Gastroenterology,2007,13(34):4539-4550. 被引量：75
  • 2Clark JM. The epidemiology of nonalcoholic fatty liver diseasein adults. J Clin Gastroenterol 2006; 40 Suppl 1: S5-10 [PMID:16540768 DOI: 10.1097/01.mcg.0000168638.84840.ff].
  • 3Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liverdisease: a global perspective. Semin Liver Dis 2008; 28: 339-350[PMID: 18956290 DOI: 10.1055/s-0028-1091978].
  • 4Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, HortonJD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepaticsteatosis in an urban population in the United States: impact ofethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI:10.1002/hep.20466].
  • 5Byrne CD. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liverdisease, insulin resistance and ectopic fat: a new problem in diabetesmanagement. Diabet Med 2012; 29: 1098-1107 [PMID: 22672330DOI: 10.1111/j.1464-5491.2012.03732.x].
  • 6Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, IyerSP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, GrazianoMP. Niemann-Pick C1 Like 1 protein is critical for intestinalcholesterol absorption. Science 2004; 303: 1201-1204 [PMID:14976318 DOI: 10.1126/science.1093131].
  • 7Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA,Braun MP, Crona JH, Davis HR, Dean DC, Detmers PA, GrazianoMP, Hughes M, Macintyre DE, Ogawa A, O'neill KA, Iyer SP,Shevell DE, Smith MM, Tang YS, Makarewicz AM, UjjainwallaF, Altmann SW, Chapman KT, Thornberry NA. The target ofezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl AcadSci USA 2005; 102: 8132-8137 [PMID: 15928087 DOI: 10.1073/pnas.0500269102].
  • 8Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, OkazakiM, Ishii H, Yoshida M. Ezetimibe improves liver steatosis andinsulin resistance in obese rat model of metabolic syndrome. FEBSLett 2007; 581: 5664-5670 [PMID: 18022391 DOI: 10.1016/j.febslet.2007.11.023].
  • 9Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepaticNiemann-Pick C1-like 1 improves hepatic insulin resistance. AmJ Physiol Endocrinol Metab 2009; 297: E1030-E1038 [PMID:19654286 DOI: 10.1152/ajpendo.00343.2009].
  • 10Takase H, Dohi Y, Okado T, Hashimoto T, Goto Y, Kimura G.Effects of ezetimibe on visceral fat in the metabolic syndrome: arandomised controlled study. Eur J Clin Invest 2012; 42: 1287-1294[PMID: 23033884 DOI: 10.1111/eci.12000].

共引文献4

内科理论与实践
2023年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部